Ownership and insider activity for Context Therapeutics Inc. (CNTX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Price
| Price | $0.38 |
| Market Cap | $35M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-24 | Pasternak Andy | A-Award | 45,000 | $26K |
| 2026-06-24 | Stacey Jennifer Evans | A-Award | 45,000 | $26K |
| 2026-06-24 | West Linda | A-Award | 45,000 | $26K |
| 2026-06-24 | Smith Karen L. | A-Award | 45,000 | $26K |
| 2026-06-24 | Walker Luke Nathaniel | A-Award | 45,000 | $26K |
| 2026-06-24 | Kantoff Philip W. | A-Award | 45,000 | $26K |
| 2026-02-19 | Levit Alex C. | A-Award | 270,000 | $626K |
| 2026-02-19 | Minai-Azary Jennifer Lynn | A-Award | 275,000 | $638K |
| 2026-02-19 | Chagin Karen Deborah | A-Award | 290,000 | $673K |
| 2026-02-19 | Lehr Martin A. | A-Award | 815,000 | $1.9M |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $226603 | $341037 | $49.6M | $35.5M | $14.4M | $94.4M | $66.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $239607 | $349709 | $51.3M | $37.9M | $16.0M | $97.9M | $68.4M |
| Property, Plant & Equipment | 0 | 0 | 0 | $79535 | $15524 | $230775 | $140066 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $273548 | $467340 | $51.3M | $38.0M | $16.1M | $98.1M | $68.5M |
| Accounts Payable | $2.1M | $2.7M | $1.8M | $936330 | $2.4M | $1.5M | $2.5M |
| Short-term Debt | $21.8M | $5.9M | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $24.1M | $9.5M | $3.0M | $3.2M | $4.2M | $2.7M | $8.0M |
| Long-term Debt | 0 | $69040 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $24.2M | $17.4M | $3.0M | $3.2M | $4.2M | $2.9M | $8.0M |
| Retained Earnings | -$25.4M | -$18.8M | -$29.3M | -$44.1M | -$68.1M | -$94.8M | -$130.9M |
| Total Equity | -$24.0M | -$16.9M | $48.3M | $34.8M | $11.9M | $95.3M | $60.5M |
| Total Debt | $21.8M | $6.0M | 0 | $55078 | 0 | $219380 | $112064 |
| Net Debt | $21.6M | $5.6M | -$49.6M | -$35.4M | -$14.4M | -$94.2M | -$65.9M |
| Working Capital | -$23.9M | -$9.2M | $48.2M | $34.6M | $11.9M | $95.1M | $60.3M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 5.81 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 6.94 |
Profitability
| Return on Equity | -82.06% |
| Return on Invested Capital | -126.84% |
| Return on Assets | -99.62% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CLNN · CNTB · IFRX · IMA · KLRS · MGNX · ORMP
Explore sector: Healthcare · Biotechnology
More sections of CNTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks